计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab175494-100μg |
100μg |
现货 ![]() |
| |
| Ab175494-1mg |
1mg |
现货 ![]() |
| |
| Ab175494-5mg |
5mg |
现货 ![]() |
| |
| Ab175494-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Clazakizumab (anti-IL-6), 白细胞介素 6 抑制剂 |
|---|---|
| 别名 | 克拉扎珠单抗 | 克拉唑珠单抗(抗 IL-6) |
| 英文别名 | Interleukin BSF 2 antibody | B cell differentiation factor antibody | B cell stimulatory factor 2 antibody | B-cell stimulatory factor 2 antibody | BSF 2 antibody | BSF-2 antibody | BSF2 antibody | CDF antibody | CTL differentiation factor antibody | Cyto |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 生化机理 | 具有多种生物功能的细胞因子。它是急性期反应的强效诱导剂。在 B 细胞最终分化为分泌 Ig 的细胞过程中发挥重要作用 参与淋巴细胞和单核细胞的分化。诱导骨髓瘤和浆细胞瘤生长,诱导神经细胞分化 作用于 B 细胞、T 细胞、肝细胞、造血祖细胞和中枢神经系统细胞。还可作为肌动素发挥作用。它在肌肉收缩后排入血液,能促进脂肪分解,改善胰岛素抵抗。 翻译后:N- 和 O- 糖基化。 |
| 宿主种属 | 人(Human) |
| 特异性 | IL6 |
| 种属反应性 | 人(Human),小鼠(Mouse),食蟹猴(Cynomolgus monkey) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 白细胞介素 6 抑制剂 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 145.24 kDa |
| 纯化方法 | Protein A purified |
| 纯度 | >95% (SDS-PAGE&SEC) |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1236278-28-6 |
| 分子类型 | 抗体 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
Clazakizumab (anti-IL-6) (Ab175494) - ELISA
Immobilized Recombinant Human IL-6 protein (rp156005) at 1.0 μg/mL can bind Clazakizumab (anti-IL-6) (Ab175494) with the EC₅₀ of 56.73 ng/mL.
Clazakizumab (anti-IL-6) (Ab175494) - SEC
The purity of Clazakizumab (anti-IL-6) (Ab175494) is more than 95% verified by HPLC.
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | Ab175494 | |
| 分析证书 | Ab175494 | |
| 分析证书 | Ab175494 |
¥579.90
¥447.92
¥669.90
¥535.92
¥359.90
¥569.90
¥299.90
¥289.90
¥299.90
¥447.92
¥199.90
| 1. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. (2011) A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.. Expert Opin Biol Ther, 11 (12): (1663-8). [PMID:21995322] |
| 2. Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. (2016) The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.. Arthritis Rheumatol, 68 (9): (2163-73). [PMID:27059799] |
| 3. Ma JD, Heavey SF, Revta C, Roeland EJ. (2014) Novel investigational biologics for the treatment of cancer cachexia.. Expert Opin Biol Ther, 14 (8): (1113-20). [PMID:24707881] |
| 4. FitzGerald O. (2016) Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option?. Nat Rev Rheumatol, 12 (6): (318-9). [PMID:27215204] |
| 5. Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P. (2015) The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.. Arthritis Rheumatol, 67 (10): (2591-600). [PMID:26138593] |